Pharmacogenomic Data Might Suffice For Retrospective Analysis, FDA's Temple Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials could be examined in a two-step process, Office of Medical Policy Director Temple says during workshop on pharmacogenomics in drug development. The data from the second half a trial could test a hypothesis generated from examining the first half if the data are "very persuasive."